secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001551152-24-000002
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie updates Q4 and FY 2023 adjusted EPS guidance for $282M IPR&D expense
---------------------------------------------------------------------------

- Q4 2023 acquired IPR&D and milestones expense of $282M pre-tax reduces GAAP and adjusted EPS by $0.15.
- Updated Q4 2023 adjusted diluted EPS guidance range: $2.72 - $2.76 (prior $2.87 - $2.91).
- Full-year 2023 adjusted diluted EPS guidance now $11.04 - $11.08 (prior $11.19 - $11.23).
- Full-year 2023 acquired IPR&D and milestones expense totals $778M.
- AbbVie notes these expenses are inherently unforecastable; final Q4 results may differ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/0001551152-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/abbv-20240105.htm
  HTML page:      https://secwatch.observer/filing/0001551152-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer